Clinical Trials Week
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Clinical Trials Week
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Colon Cancer Therapy
Reports from Harvard University add new data to research in colon cancer therapy
August 27th, 2007
Investigators publish new data in the report "CpG island methylation, response to combination chemotherapy, and patient survival in advanced microsatellite stable colorectal carcinoma." According to recent research from the United States, "The CpG island methylator phenotype (CIMP) is a distinct epigenetic phenotype in colorectal carcinoma with concordant methylation in multiple promoter CpG islands. The relationship between CpG island methylation and clinical outcomes among colorectal cancer patients treated with chemotherapy has been a controversial subject." "Utilizing real-time polymerase chain reaction (PCR; MethyLight technology), we quantified DNA methylation in...
Source: Clinical Trials Week (2007-08-27)
|
